Introduction {#s1}
============

Endophthalmitis is a microbial infection of the posterior segment of the eye ([@B1]--[@B6]). Microbes can enter this part of the eye following a penetrating injury to the globe (post-traumatic), surgery or intraocular injection (post-operative), or following hematogenous spread from another infection site (endogenous) ([@B7]--[@B15]). Hallmarks of this disease include intraocular inflammation and retinal damage, resulting in some degree of vision loss. Unfortunately, blindness can occur and removal of the globe may be necessary, even when prompt and aggressive therapeutic measures are taken ([@B5], [@B16]--[@B19]). Endophthalmitis caused by *Bacillus* spp is more devastating compared to endophthalmitis caused by other bacterial pathogens associated with this disease ([@B7], [@B20]). Among members of the *Bacillus cereus sensu lato* group (comprised of *Bacillus anthracis, Bacillus cereus*, and *Bacillus thuringiensis*), only *B. cereus* and *B. thuringiensis* have been reported as the causative agents of intraocular infection ([@B21]--[@B25]). Significant vision loss has been reported to occur in the majority of *Bacillus* endophthalmitis cases, with half of those devastating cases resulting in removal of the globe (enucleation) ([@B26]--[@B32]). *Bacillus* endophthalmitis is indeed a medical emergency, and its rapid and severe course requires immediate therapeutic attention to prevent further deterioration of the eye ([@B33]--[@B36]). At present, there is no consistently effective therapeutic strategy which mitigates vision loss during severe cases of endophthalmitis, including those caused by *B. cereus* ([@B16], [@B17], [@B37]--[@B41]). The practice of adding anti-inflammatory agents to antibiotics has not proven effective in arresting inflammation and vision loss ([@B42]--[@B45]). It is clear that other therapeutic strategies are needed to prevent the sight-threatening consequences of this infection.

*B. cereus* spp are Gram-positive, motile, β-hemolytic, spore-forming rods, and are widely disseminated in nature ([@B23], [@B24]). We reported that the *Bacillus cereus* cell wall, and secreted toxins and proteases contributed to the pathogenicity of experimental endophthalmitis ([@B5], [@B19], [@B46], [@B47]). The PlcR quorum sensing system controls the synchronized synthesis of a majority of these extracellular virulence factors and is therefore important in *Bacillus* intraocular virulence ([@B48]--[@B51]). The absence of individual *B. cereus* toxins did not blunt intraocular virulence ([@B19], [@B47]). However, in the absence of PlcR, we observed delayed evolution, but not complete attenuation of *Bacillus* endophthalmitis, suggesting the contribution of the bacterial cell wall or other components to this disease ([@B49]).

We reported that metabolically inactive *B. cereus* triggered robust intraocular inflammation, suggesting that cell wall components contribute to the activation of pro-inflammatory pathways ([@B5]). *B. cereus* have an architecturally unique envelope. In addition to peptidoglycan, lipoteichoic acid, and lipoproteins, which are all common among Gram-positive ocular pathogens, the envelope of some *B. cereus* has flagella and a paracrystalline surface protein called the S-layer protein (SLP) ([@B52]--[@B56]). Structurally, SLPs are widely diverse among species and sequence similarities from different species are low.

Since SLPs are major surface antigens, the contributions of SLPs to microbial pathogenesis have been studied in some model organisms ([@B56]--[@B63]). As the outermost layer of the surface of some bacterial strains, SLPs promote adherence of bacteria to cell membranes and extracellular matrix components, and also contribute to biofilm formation ([@B64]--[@B68]). SLPs also act as barrier, protecting bacteria from complement-mediated phagocytosis and killing ([@B69]--[@B72]). A recent report from our laboratory demonstrated that the absence of *Bacillus* SlpA significantly reduced endophthalmitis disease severity in mice ([@B73]). We also demonstrated that *Bacillus* SLP preparations activated nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and induced the expression of inflammatory mediators from retinal cells ([@B73]). However, the underlying mechanisms by which SLPs impact endophthalmitis pathogenesis remains unclear.

The ocular environment is immune privileged, and its inner tissues contain different types of cells that not only maintain the structural integrity and homeostasis of this tissue, but also act as innate immune cells which express several innate receptors ([@B74]--[@B81]). During endophthalmitis, TLRs on retinal cells sense invading microbes and induce the production of inflammatory mediators, which leads to recruitment of polymorphonuclear neutrophils (PMN) into the eye ([@B79], [@B82]--[@B84]). Almost all TLRs signal through the myeloid differentiation primary response gene-88 (MyD88) dependent pathway. In addition to MyD88 pathway, TLR4 can mediate signaling through the Toll/interleukin-1 receptor (TIR) domain containing adaptor-inducing interferon-β (TRIF) pathway ([@B85]--[@B88]). We reported that the inflammatory response in *Bacillus* endophthalmitis is primarily facilitated through TLR2 and TLR4, but not through TLR5 ([@B89]--[@B91]). The absence of TLR2 or TLR4 resulted in less PMN infiltration, inflammatory mediator production, and pathological damage during *Bacillus* endophthalmitis ([@B90], [@B91]). Blocking TLRs in this disease may effectively blunt inflammation. Identifying *B. cereus* ligands that trigger these innate pathways may help us to more clearly understand the pathological events of this disease.

*Bacillus* endophthalmitis is at or near the top of the list of rapidly blinding ocular diseases, but the level of understanding of the host/pathogen relationship in this disease is fairly limited. The earliest host response in *Bacillus* endophthalmitis is the activation of TLRs that drive the intense intraocular inflammation. Since SLPs activated NF-κB and triggered the production of proinflammatory mediators in human retinal Muller cells, we hypothesized that *B. cereus* SLPs initiate early events in endophthalmitis pathogenesis through interactions with retinal cells and by activating innate pathways. Results from this study will broaden our understanding about the mechanisms of early and potentially damaging immune response and may aid in the development of potential therapeutics to prevent inflammation and vision loss during *Bacillus* endophthalmitis.

Materials and Methods {#s2}
=====================

Bacterial Strains
-----------------

*B. thuringiensis subsp. galleriae* NRRL 4045 (WT) or its isogenic SLP deficient mutant (Δ*slpA*) ([@B73], [@B92]) were used to initiate experimental endophthalmitis in mice, as previously described ([@B89]--[@B91], [@B93]--[@B98]). *Staphylococcus aureus* strain 8325-4, *Enterococcus faecalis* strain E99, *Staphylococcus epidermidis* ATCC 12228, and *Streptococcus pneumoniae* strain TIGR4 were used for the preparation of bacterial cell envelopes.

Bacterial Adherence Assay
-------------------------

To quantify bacterial attachment to human retinal Muller cells (MIO-M1; a kind gift from Dr. Astrid Limb, UCL Institute of Ophthalmology, London), human retinal pigment epithelial cells (ARPE-19; American Type Culture Collection, Manassas, VA), and retinal photoreceptor-like 661W cells ([@B99]), we used an aerobic bacterial adherence assay. Immortalized human retinal pigmented epithelial (ARPE-19) and Muller cells were cultured in Dulbecco\'s Modified Eagle\'s Medium (DMEM)/F-12 (GIBCO, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS, Sigma Aldrich, St. Louis MO) and 1% Pen Strep (GIBCO) Retinal photoreceptor-like 661W cells were cultured in DMEM containing GlutaMAX^TM^-l (GIBCO), supplemented with 10% (v/v) FBS ([@B100]--[@B103]). All cells were maintained in a humidified 5% CO~2~ incubator at 37°C.

Confluent monolayers of each of these cell types (\~2 × 10^6^ cells) were grown in 6-well plates, and transferred to antibiotic- and serum-free DMEM 6 h prior to performing the adherence assay. Overnight cultures of WT and Δ*slpA B. thuringiensis* were harvested by centrifugation and washed twice with DMEM to exclude the effects of secreted proteins, including any toxins. Antibiotic- and serum-free medium were removed from the cells, and bacteria were added to the wells at a multiplicity of infection (MOI) of 20 in a total volume of 2 ml DMEM. Equal numbers of WT and Δ*slpA B. thuringiensis* bacteria were added to cell free wells as controls. Cell-free controls were used to verify whether bacteria adhered to the plastic surface of the six- well plates. After a 40 min incubation in a humidified 5% CO~2~ incubator at 37°C, retinal cells and adherent bacteria were washed twice with PBS. Adherent cells were then removed with a tissue cell scraper, vortexed, and serially diluted to quantify the adherent bacteria. The percent of adherent bacterial cells was calculated as the ratio of recovered bacteria to input bacteria multiplied by 100 ([@B63], [@B66], [@B67], [@B104]).

Isolation of Primary Neutrophils From Mice
------------------------------------------

Primary neutrophils were collected from mouse bone marrow by using a neutrophil isolation kit (MACS, Miltnyl Biotech, Gladbach, Germany) according to the manufacturer\'s instructions. Femurs were harvested from adult C57BL/6J mice. Bone marrow was collected in a 50 mL Falcon tube containing RPMI media (GIBCO) with 10% FBS (Sigma Aldrich) using a 10 ml syringe. The bone marrow was then centrifuged and washed with wash buffer (PBS, pH 7.2, 0.5% bovine serum albumin (BSA), and 2 mM EDTA). Cells were counted using a hemocytometer. For every 5 × 10^7^ total cells, 200 μL of wash buffer and 50 μL neutrophil biotin-antibody cocktail were added. Cells were mixed and incubated for 10 min at 4°C. Cells were then washed and the pellet was resuspended in 400 μL of wash buffer and 100 μL of anti-biotin microbeads. Cells were mixed and incubated at 4°C. After 15 min, cells were washed and resuspended to 10^8^ cells in 500 μL of buffer. For magnetic separation, an appropriate MACS column and separator were chosen according to the number of total cells and number of neutrophils. The LS column was used and placed inside a MACS separator. A 15 mL tube was placed under the column and the column was washed with 3 mL of wash buffer. When the wash buffer was completely removed, the 15 mL tube was replaced with a new one. The total sample (500 μL) was then loaded onto the column, and 3 mL of wash buffer was added 3 times onto the column and cells were collected. Cells were counted and centrifuged at 100 × *g* for 10 min, and resuspended in RPMI medium ([@B96], [@B105], [@B106]). One group of isolated cells was then immunolabeled with Ly6G and CD11 antibodies, washed, and fixed as previously described ([@B107]). Samples were analyzed using a MacsQuant flow cytometer and MacsQuantify software (Miltenyi Biotec). Neutrophil purity in each isolation was \~85.6%.

Bacterial Phagocytosis Assay
----------------------------

Human retinal Muller cells (MIO-M1), neutrophil like HL-60 cells, and mouse primary neutrophils were used in a gentamicin exclusion assay to assess the impact of SLPs on phagocytosis. Undifferentiated HL-60 cells were differentiated into neutrophil like-cells by adding 1.3% DMSO for 6 days ([@B108]--[@B110]). After 6 days, cells had neutrophil-like morphology, as confirmed by microscopy ([@B5]). Approximately 1 × 10^5^ of these cells were incubated at 20 MOI (\~2 × 10^6^) with WT or Δ*slpA B. thuringiensis* for 90 min. One group of cells was washed and treated with 200 μg/mL gentamicin for 60 min to kill all extracellular bacteria, and another group of cells was centrifuged, washed and lysed with 0.5% Triton X-100. This later group contained intra- and extracellular bacteria. After 60 min, the gentamicin-treated cells were centrifuged, washed to remove the residual antibiotic, and lysed with 0.5% Triton X-100. This group represented only the intracellular bacteria. Equal numbers of WT and Δ*slpA B. thuringiensis* (\~2 × 10^6^ in 2 mL) were incubated with 200 μg/mL gentamicin for 60 min and used as a control ([@B96], [@B104], [@B111]). CFU were enumerated by serial dilution and plating.

Preparation of Bacterial Cell Envelopes
---------------------------------------

*B. thuringiensis subsp. galleriae* NRRL 4045 (WT) and its isogenic SLP deficient mutant (Δ*slpA*), *S. aureus* 8325-4, *E. faecalis* E99, and *S. epidermidis* strain ATCC 12228 were each grown for 18 h at 37°C in brain heart infusion (BHI; VWR, Radnor PA) broth and 20 μl aliquots were removed, serially diluted, and plated to quantify bacteria. *S. pneumonia* was grown in Todd Hewitt Broth (THB; VWR) with 0.5% yeast extract and also grown for 18 h at 37°C. Cultures were harvested by centrifugation at 3,000 × *g* for 15 min at 4°C, and washed twice with PBS (pH 7.4) in endotoxin free water (HyPure cell culture grade water, GE Healthcare Life Science, Logan UT). Pellets were resuspended with equal volumes of PBS and heat inactivated at 65°C for 15 min. Sterility was tested by spread plating an aliquot of each culture onto a BHI agar plate. Cells were then centrifuged at 3,000 × *g* for 15 min, and pellets were washed twice with equal volumes of PBS. The bacterial pellets were then lyophilized, resuspended with equal volumes of PBS, and diluted to the required concentrations for use in the TLR2 and TLR4 reporter assays ([@B5], [@B73], [@B112]).

Purification of *Bacillus* SLP
------------------------------

WT and Δ*slpA B. thuringiensis* were grown for 18 h at 37°C in BHI, harvested by centrifugation at 3,000 × *g* for 15 min at 4°C, and washed twice with chilled HyPure cell culture grade water (GE Healthcare Life Science). As previously described, pellets were then resuspended in 1/10th of the initial volume of 3M guanidine hydrochloride (GHCL; pH 2.5; Sigma Aldrich) and incubated at 37°C for 1 h. The extracted SLP was separated from the pellets by centrifugation at 18,000 × *g* at 4°C for 15 min. Supernatants were dialyzed (Pur-A-Lyzer^TM^ 50kDa dialysis kit, Sigma Aldrich) against 2L of tris/HCL (pH 8.0; Research Products International Corporation, Mt. Prospect, IL) at 4°C for 24 h with four exchanges of dialysis buffer to remove residual GHCL. Protein concentrations were quantified by bicinchoninic acid assay (Sigma Aldrich) according to the manufacturer\'s instructions. Endotoxin levels were quantified using the Pierce LAL chromogenic endotoxin kit (ThermoFisher Scientific, MA) according to the manufacturer\'s instructions. Purity was confirmed by PAGE and Coomassie staining, as previously described ([@B73], [@B92]).

TLR2/TLR4 Reporter Assay
------------------------

HEK-Blue^TM^ cells were purchased from Invivogen (San Diego, CA) and used as previously described ([@B73]). HEK-Blue™ hTLR2 and HEK-Blue™ hTLR4 were used for the recognition of TLR2 and TLR4 agonists, respectively. hTLR2 and hTLR4 cells were cultured (up to 20 passages) in DMEM containing GlutaMAX^TM^-l (GIBCO), supplemented with 10% (v/v) FBS (Sigma Aldrich) and HEK-Blue Selection antibiotics (Invivogen) in a humidified 5% CO~2~ incubator at 37°C. hTLR2 and hTLR4 reporter cell lines were treated with bacterial envelopes, or SLP fractions from WT or Δ*slpA B. thuringiensis* with or without the synthetic TLR2/4 inhibitor OxPAPC (Invivogen) to assess receptor activation/inhibition ([@B73], [@B89]).

*B. thuringiensis, S. aureus, S. epidermidis* at 10^6^ envelopes/20 μl, and *E. faecalis* and *S. pneumoniae* at 10^8^ envelopes/20 μl were used to assess TLR2/4 activation. The envelope inoculum number was determined based on the equivalent number of viable organisms present during early infection ([@B5]). To measure the TLR2/4 activation by purified SLP, 10 μg/ml SLP from WT *B. thuringiensis* was used. The SLP fraction from Δ*slpA B. thuringiensis* was used as an extract control. In both assays, Pam3Csk4 (0.25 ng/mL; Invivogen) was used as a positive control for the hTLR2, and a negative control for the hTLR4 reporter assays. LPS (100 ng/mL; Invivogen) was used as a positive control for the hTLR4, and a negative control for the hTLR2 reporter assays. Endotoxin free water (GE Healthcare Life Science) was used as a negative control for both hTLR2 and hTLR4 reporter assays. To inhibit TLR2/4 activation, an oxidized phospholipid OxPAPC (0.15μg/μL) was used with Pam3Csk4, LPS, and purified SLP ([@B113]). Samples, controls, and inhibitors (20 μL) were added to appropriate wells of 96-well plates. hTLR2 and hTLR4 reporter cells at 50 to 80% confluency were washed with pre-warmed PBS (pH 7.4; GIBCO). After detaching the cells with PBS, hTLR2 cells were resuspended to 5.0 × 10^4^ and hTLR4 cells to 2.5 × 10^4^ in 180 μl of HEK-Blue^TM^ Detection medium (Invivogen). For the OxPAPC-treated groups, 5.0 × 10^4^ /160 μl hTLR2 and 2.5 × 10^4^/160 μl hTLR4 cell suspensions were prepared. Each cell suspension was immediately added into the appropriate wells of the 96-well plates, and incubated for 14 h at 37°C in 5% CO~2~. Activation of TLR2 and TLR4 (production of SEAP) was measured using a spectrophotometer at 620-655nm. TLR2/4 activation was presented as percent of TLR2/4 activation relative to the positive controls Pam3Csk4 and LPS ([@B73], [@B89], [@B114]).

Mice and Intraocular Infection
------------------------------

All *in vivo* experiments were performed with C57BL/6J mice purchased from Jackson Labs (Bar Harbor ME, Stock No. 000664). Mice were housed on a 12 h on/12 h off light cycle in biohazard level 2 conditions and acclimated for at least 2 weeks to equilibrate their microbiota. Mice were 8--10 weeks of age at the time of the experiments. Mice were sedated using a combination of ketamine (85 mg/kg body weight; Ketathesia, Henry Schein Animal Health, Dublin, OH) and xylazine (14 mg/kg body weight; AnaSed, Akorn Inc., Decatur, IL). Four groups of C57BL/6J mice were used in this experiment. The first two groups of mice were infected with 100 CFU WT *B. thuringiensis*/0.5 μl BHI, and the third group was infected with 100 CFU Δ*slpA B. thuringiensis*/0.5 μl BHI into the right eye using a sterile glass capillary needle, as previously described ([@B73], [@B89]--[@B91], [@B93], [@B95]--[@B98]). The fourth group was not infected. At 4 h postinfection, the second group of infected mice and fourth group of uninfected mice were intravitreally treated with 30 ng/μL OxPAPC. At 10 h postinfection, electroretinography was performed prior to euthanasia by CO~2~ inhalation, and then eyes were harvested for quantitation of viable intraocular bacteria, retinal function, and PMN infiltration, and analysis of ocular architecture by histology, as described below.

Intraocular Bacterial Quantitation
----------------------------------

As previously described ([@B73], [@B89]--[@B91], [@B93], [@B94], [@B96]--[@B98]), eyes were harvested from euthanized mice at specific time points, homogenized in 400 μl PBS with sterile 1-mm glass beads (BioSpec Products, Inc., Bartlesville OK), serially diluted 10-fold in PBS, and plated onto BHI agar plates.

For *in vivo* bacterial growth analysis at different time points, experimental endophthalmitis was induced by intravitreally injecting approximately 100 CFU WT *B. thuringiensis* in 0.5 μl BHI into the right eyes of mice. At 4 h postinfection, one group of infected eyes was treated with OxPAPC, and another group served as the untreated control. At 2 h intervals thereafter, eyes were harvested for quantitation of intraocular bacterial growth ([@B73], [@B89]--[@B91], [@B93], [@B94], [@B96]--[@B98]).

*In vitro* Bacterial Quantitation
---------------------------------

Potential antimicrobial activity of OxPAPC was assessed *in vitro*. WT *B. thuringiensis* was cultured for 18 h at 37°C with aeration in BHI medium. The culture was then diluted to 10^3^ CFU/mL in fresh BHI containing 0.1, 1, or 10 μg/mL OxPAPC, and incubated for 18 h at 37°C. At 2 h intervals during this period, 20 μl aliquots were serially diluted 10-fold in PBS, and plated onto BHI agar plates ([@B73], [@B93]).

Retinal Function Analysis
-------------------------

Electroretinography (ERG) was used to quantify retinal function as previously described ([@B5], [@B47], [@B51], [@B73], [@B91], [@B93], [@B94], [@B96], [@B97]) in *Bacillus-*infected and OxPAPC-treated eyes. After infection/treatment, mice were dark adapted for 6 h. Mice were then anesthetized as described above, and pupils were dilated with topical phenylephrine (Akorn, Inc., IL). Two gold wire electrodes were placed onto each cornea. Reference electrodes were attached to the tail and forehead. Eyes were then stimulated by five flashes of white light (1,200 cd s/m^2^) and retinal responses were recorded as A-wave (retinal photoreceptor cell function) and B-wave (bipolar cell, Muller cell, and second order neuronal function) amplitudes for infected eyes and compared with the uninfected eyes of the same animal (Espion E2 software, Diagnosys LLC, Lowell MA) ([@B5], [@B47], [@B51], [@B73], [@B91], [@B93], [@B94], [@B96], [@B97]).

Histology
---------

Infected/treated eyes were harvested from euthanized mice at 10 h postinfection. Harvested eyes were incubated in High Alcoholic Prefer fixative for 30 min, and then transferred to 70% ethanol. Paraffin-embedded eyes were sectioned and stained with hematoxylin and eosin (H&E) ([@B73], [@B89], [@B90], [@B94], [@B96]--[@B98]).

Inflammatory Cell Influx
------------------------

Inflammatory cell infiltration was estimated by quantifying myeloperoxidase (MPO) using a sandwich ELISA (Hycult Biotech, Plymouth Meeting PA), as previously described. At 10 h postinfection, eyes were harvested, transferred into PBS supplemented with proteinase inhibitor cocktail (Roche Diagnostics, Indianapolis, IN) and homogenized using 1-mm sterile glass beads (BioSpec Products, Inc.). Uninfected eye homogenates were the negative controls. The lower limit of detection for this assay was 2 ng/ml ([@B73], [@B89], [@B91], [@B96]--[@B98]).

Statistics
----------

GraphPad Prism 7 was used for the statistical analysis (Graph-Pad Software, Inc., La Jolla, CA). Mann-Whitney *U*-test was used for statistical comparisons unless otherwise specified. *P*-values of \<0.05 were considered significant ([@B93], [@B94], [@B96], [@B115]). For all assays, *N*-values represented single biological replicates.

Results {#s3}
=======

SlpA Contributes to the Adherence of *Bacillus* to Retinal Cells
----------------------------------------------------------------

As *Bacillus* migrate within the posterior segment of the eye, organisms physically interact with retinal cells ([@B5], [@B73]). The first step in this interaction is adherence, and we hypothesized that SLPs mediated that interaction. An experiment to evaluate the role of SlpA in bacterial attachment to retinal cells is depicted in [Figure 1](#F1){ref-type="fig"}. In the absence of SlpA, significant reductions in percent Δ*slpA B. thuringiensis* adherence were seen with human retinal Muller MIO-M1 cells (*P* \< 0.0001, [Figure 1A](#F1){ref-type="fig"}), retinal pigment epithelial cells (ARPE-19) (*P* = 0.0022, [Figure 1B](#F1){ref-type="fig"}), and retinal photoreceptor-like 661W cells (*P* = 0.0022, [Figure 1C](#F1){ref-type="fig"}) compared to that of WT *B. thuringiensis*. No bacteria were recovered from cell-free controls, suggesting no adherence to the plastic surface of the wells. These findings demonstrated that SlpA contributed to bacterial adherence to retinal cells, suggesting that SLPs may play a role in bacterial adherence to retinal cells during the early stage of *Bacillus* endophthalmitis.

![*Bacillus* SLP contributes to adherence to retinal cells *in vitro*. Three different retinal cell types were incubated with WT *B. thuringiensis* or Δ*slpA B. thuringiensis* for 40 min to assess bacterial adherence. Compared to WT, Δ*slpA B. thuringiensis* demonstrated a significant reduction in adherence to **(A)** human retinal Muller MIO-M1 cells, **(B)** human retinal pigment epithelial (ARPE-19) cells, and **(C)** retinal photoreceptor-like 661W cells. WT and Δ*slpA B. thuringiensis* in cell-free wells served as controls. Values represent the mean ± SEM of *N* ≥ 5 for at least two separate experiments; \**P* \< 0.05.](fimmu-11-00215-g0001){#F1}

SlpA Protects *Bacillus* From Phagocytosis
------------------------------------------

Interactions between *Bacillus* and retinal and immune cells may be important in initiating the subsequent immune response. A gentamicin (Gen) exclusion phagocytosis assay was used to determine the role of SlpA in internalization by human retinal Muller cells (MIO-M1), neutrophil like HL-60 cells, and mouse primary neutrophils ([Figure 2](#F2){ref-type="fig"}). Significant increases in internalization of Δ*slpA B. thuringiensis* were seen with human retinal Muller cells (*P* = 0.0122, [Figure 2A](#F2){ref-type="fig"}), neutrophil like HL-60 cells (*P* = 0.0049, [Figure 2B](#F2){ref-type="fig"}), and mouse primary neutrophils (*P* = 0.0002, [Figure 2C](#F2){ref-type="fig"}) compared to that of WT *B. thuringiensis*. No bacteria were recovered after the incubation with gentamicin, indicating that WT and Δ*slpA B. thuringiensis* were susceptible to the antibiotic. Taken together, these results demonstrated that SlpA directly interfered with internalization by human retinal Muller cells and professional phagocytic cells, suggesting that SLP may protect the pathogen from phagocytosis during active infection.

![*Bacillus* SLP provides protection from phagocytosis. Muller cells, neutrophil-like HL60 cells, and mouse primary neutrophils were incubated with WT or Δ*slpA B. thuringiensis* for 90 min. Cells were then treated with gentamicin for 60 min to kill external bacteria. Compared to WT *B. thuringiensis*, internalization of Δ*slpA B. thuringiensis* was significantly greater by **(A)** human retinal Muller cells, **(B)** neutrophil-like HL-60 cells, and **(C)** mouse primary neutrophils. Gen+, Gentamicin treated; Gen-, Gentamicin untreated. Values represent mean ± SEM of *N* ≥ 5 for at least two separate experiments; \**P* \< 0.05. Dashed lines represent the initial bacterial inoculum.](fimmu-11-00215-g0002){#F2}

*Bacillus* Envelope Contains an Unexpected TLR4 Agonist
-------------------------------------------------------

Mice which lack functional TLR2 or TLR4 have a reduced intraocular inflammatory response upon intravitreal challenge with *Bacillus* ([@B90], [@B91]), suggesting that this organism interacts with those receptors. Here, we investigated whether the envelopes of common Gram-positive endophthalmitis pathogens (WT and Δ*slpA B. thuringiensis, S. aureus, S. epidermidis, E. faecalis*, and *S. pneumoniae*) activated TLR2 and TLR4 in hTLR2 or hTLR4 reporter cell line assays ([Figure 3](#F3){ref-type="fig"}). Envelope preparations from all five species activated TLR2 ([Figure 3A](#F3){ref-type="fig"}). Surprisingly, only WT *B. thuringiensis* envelopes significantly activated TLR4 (*P* = 0.0286), whereas other Gram-positive endophthalmitis pathogens did not ([Figure 3B](#F3){ref-type="fig"}). Activation of TLR4 was significantly higher (*P* = 0.0286) in WT *B. thuringiensis* than Δ*slpA*. These results suggest that the *Bacillus* envelope possesses universal TLR2 agonists and one or more unexpected TLR4 agonists.

![*Bacillus* envelope possesses an unexpected TLR4 agonist. HEK-Blue™ hTLR2 and hTLR4 reporter cells were incubated with envelope preparations of WT or Δ*slpA B. thuringiensis, S. aureus, S. epidermidis, E. faecalis*, or *S. pneumoniae* for 14 h at 37°C in 5% CO~2~ **(A)** The envelopes of WT *and* Δ*slpA B. thuringiensis, S. aureus, S. epidermidis, E. faecalis*, and *S. pneumoniae* activated TLR2. **(B)** Among the five Gram-positive endophthalmitis pathogens, only the envelopes of WT *B. thuringiensis* activated TLR4. Values represent mean ± SEM of *N* ≥ 4 for at least two separate experiments; \**P* \< 0.05.](fimmu-11-00215-g0003){#F3}

SLP of *Bacillus* Is Necessary for Activation of Both TLR2 and TLR4
-------------------------------------------------------------------

SLP from WT *B. thuringiensis* induced inflammatory mediator expression from retinal Muller cells by activating the canonical NF-κB pathway ([@B73]). Since the envelope of *B. thuringiensis* activated TLR2/4, we next determined whether its SLP activated TLR2 and TLR4 in similar assays. Purified SLP from WT *B. thuringiensis* activated TLR2 to a significantly higher degree than the extract control from Δ*slpA B. thuringiensis* (*P* = 0.0003; [Figure 4A](#F4){ref-type="fig"}). Purified SLP from *B. thuringiensis* also significantly activated TLR4 to a greater degree than did the extract control from Δ*slpA B. thuringiensis* (*P* = 0.0003; [Figure 4B](#F4){ref-type="fig"}). To further evaluate the activation of TLR2 and TLR4 by SLP, we included an oxidized phospholipid (OxPAPC) in the reporter assay to inhibit the activation of both TLR2 and TLR4. OxPAPC significantly inhibited TLR2 activation by the TLR2 agonist Pam3Csk4 and by purified SLP from WT *B. thuringiensis* (*P* = 0.0022; [Figure 4C](#F4){ref-type="fig"}). OxPAPC also significantly reduced the activation of TLR4 by LPS and by purified SLP (*P* = 0.0022; [Figure 4D](#F4){ref-type="fig"}) SLP-mediated TLR2 and TLR4 activation in OxPAPC treated groups were 74.7 and 70.7% lower than TLR2 or TLR4 activation in the untreated groups, respectively. Together these findings demonstrated that SLPs not only activated TLR2, but also TLR4. This suggests that SLP is a potent stimulator of both TLR2 and TLR4 innate pathways, and may contribute to the production of inflammatory mediators during experimental endophthalmitis.

![*Bacillus* SLP is a potent activator of TLR2 and TLR4. **(A)** SLP from WT *B. thuringiensis* activated TLR2 to a significantly greater degree than did the extract control (Δ*slpA*). LPS, a TLR4 agonist, was used as a negative control. **(B)** WT SLP significantly activated TLR4 compared to the extract control (Δ*slpA*). Pam3Csk4, a TLR2 agonist, was used as a negative control. **(C)** Treatment with OxPAPC significantly inhibited TLR2 activation by the positive control Pam3Csk4 and WT SLP. **(D)** Treatment with OxPAPC significantly inhibited TLR4 activation by the positive control LPS and WT SLP. Values represent mean ± SEM of *N* ≥ 5 for at least two separate experiments; \**P* \< 0.05.](fimmu-11-00215-g0004){#F4}

Inhibition of TLR2/4 Activation Resulted in Reduced Bacterial Burden During Experimental *Bacillus* Endophthalmitis
-------------------------------------------------------------------------------------------------------------------

There were no changes the intraocular bacterial burden in TLR2^−/−^ or TLR4^−/−^ mice infected with *B. cereus* ([@B90], [@B91]). Here, we investigated whether inhibition of both TLR2 and TLR4 activation affected bacterial growth during experimental endophthalmitis. [Figure 5A](#F5){ref-type="fig"} depicts the experimental design. Inhibition of the TLR2/4 pathways by OxPAPC significantly reduced the bacterial load in WT infected mouse eyes relative to that of untreated eyes (*P* = 0.0007; [Figure 5B](#F5){ref-type="fig"}) at 10 h postinfection. There was no difference in bacterial load observed between WT and Δ*slpA* infected mouse eyes (*P* = 0.3680; [Figure 5B](#F5){ref-type="fig"}). At this time, the growth rates of WT and Δ*slpA B. thuringiensis* infected eyes (2.2 and 1.9 h^−1^) were faster than that in the WT-infected and OxPAPC treated eyes (0.76 h^−1^). To determine whether OxPAPC possessed bactericidal activity, we analyzed WT *B. thuringiensis* growth in the presence of increasing concentrations (0.1, 1, and 10 μg/mL) of OxPAPC. As shown in [Figure 5C](#F5){ref-type="fig"}, OxPAPC did not alter bacterial growth *in vitro* at any of the concentrations tested. To investigate whether this phenomenon of reduced bacterial load only occurred *in vivo*, we assessed bacterial growth at varying time points after infection after treatment with OxPAPC and observed that bacterial concentrations were significantly lower in OxPAPC treated groups at 8 h (*P* = 0.0260), 10 h (*P* = 0.0043) and 12 h (*P* = 0.0152) postinfection ([Figure 5D](#F5){ref-type="fig"}). Taken together, these findings demonstrated that inhibition of TLR2/4 activation contributed to reduced bacterial burden during experimental *Bacillus* endophthalmitis.

![OxPAPC treatment resulted in reduced intraocular bacterial load during *Bacillus* endophthalmitis. **(A)** Experimental design of *in vivo* inhibition of TLR2/4 activation. **(B)** C57BL/6J mouse eyes were infected with 100 CFU WT or Δ*slpA B. thuringiensis*. At 4 h postinfection WT infected eyes were treated with 30 ng/μL OxPAPC. At 10 h postinfection eyes were harvested, homogenized, and analyzed for bacterial growth. Compared to untreated WT-infected C57BL/6J mouse eyes, a significant reduction in bacterial burden was observed in the OxPAPC-treated group at 10 h postinfection. No difference in intraocular bacterial count was observed between WT and Δ*slpA* infected eyes at 10 h postinfection. Values represent mean ± SEM of log10 CFU/eye of *N* ≥ 5 eyes for at least two separate experiments. **(C)** The *in vitro* growth of WT *B. thuringiensis* in BHI was not affected by the presence of 0.1, 1, or 10 μg/mL OxPAPC. Values represent the mean ± SEM of *N* = 3; multiple comparison, 2-way ANOVA **(D)** Treatment of eyes with OxPAPC 4 h after infection with 100 CFU of WT *B. thuringiensis* resulted in decreased bacterial growth. Data represent the mean ± SEM of log10 CFU/eye of *N* ≥ 5 eyes per time point for at least two separate experiments; ns: *P* \> 0.05, \**P* \< 0.05 at all time points.](fimmu-11-00215-g0005){#F5}

Retinal Function Improved in the Absence of TLR2/4 Activation by SLP During Experimental *Bacillus* Endophthalmitis
-------------------------------------------------------------------------------------------------------------------

Since the absence of individual TLRs (TLR2 or 4) and their adaptors (MyD88 and TRIF) resulted in retained retinal function in experimental *Bacillus* endophthalmitis ([@B90], [@B91], [@B97]), we investigated whether inhibition of both TLR2/4 by OxPAPC would have a similar outcome. Analysis of retinal function and the representative waveforms of eyes infected with WT, WT-infected and OxPAPC-treated, Δ*slpA B. thuringiensis*-infected, and OxPAPC-treated only is depicted in [Figure 6](#F6){ref-type="fig"}. The A-wave amplitudes were significantly reduced in WT-infected eyes at 10 h postinfection (*P* \< 0.05) to a retained response of \~29%. Compared to WT-infected eyes, WT-infected/OxPAPC-treated, Δ*slpA*-infected, and OxPAPC-treated eyes showed significant retention of retinal function. At 10 h postinfection, the retained response of A-wave function in these groups was \~100% ([Figure 6A](#F6){ref-type="fig"}). The B-wave amplitudes were significantly reduced in the WT *B. thuringiensis*-infected eyes at 10 h postinfection (*P* \< 0.05) to a retained response of \~18% ([Figure 6B](#F6){ref-type="fig"}). This response in eyes infected/treated with WT/OxPAPC, Δ*slpA B. thuringiensis*, and OxPAPC was retained to a significantly greater degree compared to that of WT-infected and untreated eyes. The retained responses of B-waves among these groups at 10 h postinfection was \~79%. Representative waveforms demonstrating the differences in A- and B-wave amplitudes of eyes in these groups at 10 h postinfection are shown in [Figures 6C,D](#F6){ref-type="fig"}. Together, these results demonstrated that WT-infected eyes treated with the TLR2/4 inhibitor OxPAPC retained greater retinal function compared to untreated WT *B. thuringiensis*-infected eyes. These results suggested that the activation of TLR2 and TLR4 innate pathways by SLP influenced the loss of retinal function during experimental endophthalmitis.

![Inhibition of SLP-mediated TLR2/4 activation resulted in significant retention of retinal function during *Bacillus* endophthalmitis. C57BL/6J mouse eyes were injected with 100 CFU WT or Δ*slpA B. thuringiensis*. WT infected and uninfected mouse eyes were treated with 30 ng/μL OxPAPC at 4 h postinfection, and retinal function was assessed by ERG. **(A)** A-wave retention was significantly higher in WT-infected /OxPAPC-treated, Δ*slpA*-infected, and OxPAPC-treated eyes, than WT-infected/untreated eyes. **(B)** B-wave retention was also significantly higher in WT-infected/OxPAPC-treated, Δ*slpA*-infected, and OxPAPC-treated eyes than the WT-infected/untreated eyes. **(C)** Shown are representative waveforms from the uninfected contralateral eyes from each group (green). **(D)** Representative waveforms from WT-infected, WT-infected/OxPAPC-treated, Δ*slpA*-infected, and OxPAPC-treated eyes at 10 h postinfection (red). Values represent the mean ± SEM of the % amplitude retained relative to the contralateral control eye for at least two separate experiments. Data are representative of *N* ≥ 6 eyes; \**P* \< 0.05.](fimmu-11-00215-g0006){#F6}

Inflammation Was Reduced and Ocular Architecture Was Preserved in the Absence of TLR2/4 Activation by SLP During Experimental *Bacillus* Endophthalmitis
--------------------------------------------------------------------------------------------------------------------------------------------------------

PMN are the primary infiltrating cell type recruited to the site of infection during *Bacillus* endophthalmitis ([@B6], [@B82], [@B98]). Here, we examined the degree of inflammatory cell influx and retinal damage in WT-infected, WT-infected/OxPAPC-treated, Δ*slpA B. thuringiensis*-infected, and OxPAPC-treated eyes ([Figure 7](#F7){ref-type="fig"}). PMN infiltration in the eye was estimated by quantifying myeloperoxidase (MPO) in eye homogenates. MPO concentrations were significantly greater at 10 h postinfection in WT-infected eyes compared to that of WT-infected/OxPAPC-treated (*P* = 0.0016), Δ*slpA*-infected (*P* = 0.0022), and OxPAPC-treated (*P* = 0.0022) eyes ([Figure 7A](#F7){ref-type="fig"}). The levels of MPO in WT-infected/OXPAPC treated, Δ*slpA*-infected, and OXPAPC-treated eyes were 9-fold, 8-fold, and 38-fold lower compared to that of untreated WT-infected eyes. These results demonstrated that infection with Δ*slpA B. thuringiensis* and inhibition of the TLR2 and TLR4 pathways during experimental endophthalmitis each resulted in reduced MPO levels, indicating less PMN recruitment in these eyes.

![Inhibition of SLP-mediated TLR2/4 activation resulted in reduced inflammatory cell influx and preserved ocular architecture during *Bacillus* endophthalmitis. C57BL/6J mouse eyes were infected with 100 CFU WT or Δ*slpA B. thuringiensis*. Uninfected eyes, or eyes injected with WT *B. thuringiensis* were treated with 30 ng/μL OxPAPC at 4 h postinfection. **(A)** Infiltration of PMN was assessed by quantifying MPO in whole eyes by sandwich ELISA. MPO levels were significantly greater in eyes infected with WT *B. thuringiensis* than in eyes infected with WT and treated with OxPAPC, eyes infected with only Δ*slpA B. thuringiensis*, and eyes treated with OxPAPC alone. Values represent the mean ± SEM of *N* ≥ 4 eyes per group; \**P* \< 0.05. **(B)** Infected and treated eyes were harvested at 10 h postinfection and processed for hematoxylin and eosin staining. Magnification, 10×. Sections are representative of three eyes in each group.](fimmu-11-00215-g0007){#F7}

A histological comparison of WT-infected, WT-infected/OxPAPC-treated, Δ*slpA*-infected, and OxPAPC-treated eyes is depicted in [Figure 7B](#F7){ref-type="fig"}. At 10 h postinfection, the anterior and posterior segments of WT-infected/OxPAPC-treated, Δ*slpA*-infected, and OxPAPC-treated eyes were similar. The corneas and posterior segments of eyes in these groups had no inflammation and intact retinas. In contrast, untreated eyes infected with WT *B. thuringiensis* had substantial accumulation of infiltrating cells and fibrin in the posterior segment. Corneas in these eyes had significant edema, and retinal layers were detached and often indistinguishable. Together, these findings demonstrated that inhibition of the TLR2 and TLR4 pathways and infection with SlpA-deficient *B. thuringiensis* in experimental endophthalmitis had a similar outcome. In both cases, inflammation was reduced and ocular architecture was preserved. Taken together, these results suggest that SLP contributes to the pathogenesis of *Bacillus* endophthalmitis via TLR2 and TLR4.

Discussion {#s4}
==========

The host-pathogen interaction is an early event that dictates the severity and outcome of an infectious disease ([@B116]). Although the ocular environment is an immune-privileged site, innate ocular immune defense mechanisms are capable of responding to invading pathogens ([@B74], [@B75], [@B77], [@B78]). Ocular defense mechanisms can be easily overwhelmed by infection with a pathogen that cannot be effectively cleared from the eye. *B. cereus* intraocular infection produces a more robust inflammatory response than other ocular bacterial pathogens such as *S. aureus, E. faecalis, S. epidermidis, S. pneumoniae, E. coli*, and *Klebsiella pneumoniae* ([@B7], [@B73], [@B82], [@B117]). In *Bacillus* endophthalmitis, within 4 h, PMNs move into the vitreous, and within 8 h into the retinal layers. PMNs not only can disrupt vision through bystander effects on cells in the retina, but their presence in the vitreous can also block the clarity of the visual axis ([@B82], [@B98]). Though *Bacillus* endophthalmitis is a rare intraocular infection, the potential to cause blindness is high, and better therapeutic strategies are needed to improve visual outcomes.

Compared to the envelopes of other Gram-positive intraocular pathogens, the envelope of *Bacillus* contains unique components such as flagella, pili, and a protein coat composed of SLPs ([@B53]--[@B55], [@B60]). Flagella aid in the rapid movement of *Bacillus* throughout all parts of the eye, from the initial site of infection into the anterior segment within 6--12 h ([@B89]). The absence of motility affected toxin production, and therefore, non-motile *B. cereus* caused less severe disease pathogenesis ([@B19]). We also reported that infection with pili-deficient *B. cereus* led to a reduced inflammatory response in the eye, suggesting the importance of pili in that aspect of this disease ([@B93]). In a recent report ([@B73]), we demonstrated that while the absence of SlpA did not change the growth, cytotoxicity, motility, hemolytic properties, or cell wall composition of *B. thuringiensis*, the absence of SlpA significantly reduced disease severity compared to severe disease caused by the WT parental strain experimental endophthalmitis. SLPs are a major contributor to the pathogenesis of *Bacillus* endophthalmitis ([@B73]), but the underlying mechanism by which SLPs contributes to pathogenesis were unknown.

SLPs form para-crystalline protein sheets that assemble on the bacterial surface ([@B56]). SLPs and their associated proteins facilitate numerous functions that are critical to cellular physiology and survival ([@B57], [@B59]). A primary function of SLPs are to promote colonization by contributing to the adherence to host tissue ([@B68]). It has been reported that SLP of *B. anthracis* helps the pathogen to adhere to HeLa cells, and infection with a SLP-deficient *B. anthracis* resulted in attenuated infection in guinea pigs ([@B118]). A recent report suggested that SLP of *Clostridium difficle* played an important role in the colonization to human intestinal epithelial cells by contributing to bacterial adherence ([@B63]). We have observed *B. cereus* and *B. thuringiensis* near the inner limiting membrane (ILM) of the retina during experimental endophthalmitis ([@B5], [@B73]). As physical contact between pathogen and the infected tissue is the initial event of any host-pathogen interaction, we compared whether SLPs influenced *Bacillus* adherence to different types of retinal cells. Muller cells are the major retinal cells that span from the outer limiting membrane (OLM) to the ILM, providing structural and hemostasis support ([@B119]--[@B122]). Since the end feet of retinal Muller cells are located in the ILM, these might be the first retinal cells to encounter pathogens in the posterior segment. RPE cells are important for phototransduction and represent the outer blood retinal barrier. Light-sensitive photoreceptor cells are located anterior to RPE cells ([@B100]--[@B103]). A recent report suggested that although 661W cells have been used as cone photoreceptor mimics, this cell line expresses markers specific to retinal ganglion cells, such as Rbpms, Brn3b (Pou4f2), Brn3c (Pou4f3), Thy1 and γ-synuclein (Sncg), and thus are retinal ganglion cell-like ([@B99]). Here, we demonstrated that SLP plays an important role in mediating *B. thuringiensis* adherence to these cell types *in vitro*, suggesting its role in bacterial attachment to retinal cells.

Evading host defense systems is a key event in successfully establishing an infection. Some organisms are evolutionarily equipped to conceal themselves from the unfriendly environment of the host ([@B123]--[@B125]). If present, SLPs can protect microorganisms from sudden shifts in pH, exposure to radiation, and changes in mechanical and osmotic stresses. SLPs can also shield bacteria from antimicrobial peptides, lytic enzymes, and bacteriophages ([@B64]). It has been reported that the SLP in *Eubacterium yurii* provides resistance to this pathogen against phagocytosis by PMN ([@B72]). In addition to providing structural and homeostasis support, Muller cells might also protect the retina by phagocytizing microbes ([@B120], [@B126], [@B127]). Here, we investigated the role of *B. cereus* SLPs in phagocytosis by human retinal Muller cells, neutrophil like HL-60 cells, and mouse primary neutrophils. We observed significantly less internalized WT *B. thuringiensis* than the Δ*slpA B. thuringiensis* mutant in all three phagocytic cell types. These findings support a role of SLP in promoting *Bacillus* adherence and evading phagocytosis.

Innate immune responses are the host\'s first line of defense against any invading pathogen, and TLRs are a key mediator in many inflammatory diseases ([@B128], [@B129]). TLRs are critical for initiating an ocular inflammatory response to microbes during keratitis, uveitis, and endophthalmitis ([@B82], [@B89]--[@B91], [@B95], [@B130]--[@B132]). We demonstrated that during *B. cereus* endophthalmitis, TLR2 and TLR4 each directly influenced the severity of intraocular inflammation ([@B90], [@B91]). We also reported the importance of MyD88 and TRIF adaptors in the pathogenesis of *B. cereus* endophthalmitis ([@B97]). Here, we demonstrated the activation of TLR2 by the envelope of Gram-positive ocular pathogens, and of these pathogens, only the envelope of *B. thuringiensis* activated TLR4. Since *Bacillus* is Gram-positive bacterium, it possesses several universal TLR2 agonists such as peptidoglycan, lipoteichoic acid, and lipoproteins. However, TLR4 agonists had yet to be identified.

As cell wall-associated proteins, SLPs have the potential to interact with retinal innate receptors. *C. difficile* SLPs have been shown to activate innate and adaptive immunity in a TLR4-dependent manner ([@B133]). SLP from *Lactobacillus helveticus* mediated a proinflammatory response through activation of both TLR2 and TLR4 in human macrophages ([@B134]). We reported that SLP activated the major transcription factor NF-κb, and induced proinflammatory cytokine production from retinal cells, suggesting that this protein might also activate retinal innate immune pathways ([@B73]). Here, by using TLR2 and TLR4 reporter cell lines, we showed for the first time that SLP not only activated TLR2, but also TLR4.

Assessing the role of TLRs and adaptor proteins in *Bacillus* endophthalmitis has been done using specific TLR- or adaptor protein-deficient mice ([@B89]--[@B91], [@B97]). Since SLP can signal through both TLR2 and TLR4, we used the oxidized phospholipid OxPAPC to inhibit both pathways ([@B113]). OxPAPC competes with CD14, lipid binding protein, and MD2, the accessory proteins that interact with bacterial lipids, and blocks the signaling of both TLR2 and TLR4 ([@B135], [@B136]). A recent report suggested that blocking both TLR2 and TLR4 might lay the foundation for the development of therapies that target inflammasomes during Gram-negative bacterial sepsis ([@B137]). OxPAPC has been reported to inhibit LPS (for TLR4) and Pam3Csk4 (for TLR2) ligand-mediated inflammatory responses in mice ([@B138], [@B139]). Anti-inflammatory effects of OxPAPC-directed attenuation of TLR signaling in response to pathogens and pathogen associated molecular patterns (PAMPs) are well recognized ([@B140]--[@B142]). Here, we showed that OxPAPC dramatically reduced TLR2 and TLR4 activation by their agonists and by *B. cereus* SLP *in vitro*. *In vivo*, we observed an unanticipated reduction in bacterial load in the WT infected-OxPAPC treated group. In contrast, OxPAPC did not alter bacterial growth *in vitro*. We previously reported that absence of TLR2, TLR4, or TLR5 or their adaptor MyD88 did not result in alterations in bacterial burden during *Bacillus* endophthalmitis. But the absence of TRIF, which is a key adaptor for TLR4 signaling, resulted in a significantly reduced bacterial load during *Bacillus* endophthalmitis ([@B89]--[@B91], [@B97]). Here, OxPAPC treatment resulted in a reduced bacterial load in the eye from 6- to 12-h postinfection. A greater bacterial burden might be expected in tissue where an inflammatory response is insufficient; however, we did not observe this here. Deficiencies in cathelicidin-related antimicrobial peptide (CRAMP) which led to increased *S. aureus* and *Pseudomonas aeruginosa* burdens in mouse eyes with endophthalmitis and keratitis, respectively, have been reported ([@B143], [@B144]). Hence, it is reasonable to speculate that increased level of AMPs may lead to a lower bacterial burden. However, another report demonstrated that TRIF-deficient mice had low AMP expression levels in the gastrointestinal tract ([@B145]), so the physiological involvement of AMPs may be tissue- and infection-specific.

If the inflammation we observed here was ordained exclusively by bacterial burden, infections with WT or Δ*slpA B. thuringiensis* should have resulted in similar levels of inflammation, given that both strains grow similarly in the eye ([@B73]). However, the course of inflammation and retinal function loss in WT and Δ*slpA B. thuringiensis* eyes were significantly different, but the rates of bacterial growth in these groups were almost identical (2.2 and 1.99 h^−1^). Since *B. thuringiensis* did not show any growth defects in the presence of increasing concentrations of OxPAPC, the possibility arises that blocking both TLR2 and TLR4 pathways might associated with the upregulation of AMPs in the vitreous. We did not detect expression of AMPs in the retinas of WT or TLR4^−/−^ C57BL/6J mice infected with *Bacillus* at 4 h postinfection ([@B95]). Whether OxPAPC has effects other than inhibiting TLR2/4 activation or whether OxPAPC induces expression of AMPs in the retina is an open question.

The retina is a multilayered tissue containing nonregenerative light sensitive cells responsible for biochemical processes involved in proper vision ([@B100]). *Bacillus* endophthalmitis destroys these cells, resulting in retinal function loss. We reported that mice lacking individual TLRs (TLR2 or 4) and their adaptors, MyD88 and TRIF, have significant retention of retinal function during *Bacillus* endophthalmitis ([@B89]--[@B91], [@B97]). We also reported that infection with a Δ*slpA B. thuringiensis* resulted in better retention of retinal function compared to infection with a WT *B. thuringiensis* ([@B73]). Here, we observed that inhibition of both TLR2 and TLR4 signaling with OxPAPC resulted in significantly higher retained retinal function after infection with the WT strain, likely due to the preserved retinal architecture in these eyes. We reported that the absence of SlpA did not change the cytotoxic properties of *Bacillus* or altered its intraocular growth ([@B73]). Therefore, it is unlikely that the differences in retinal function loss between untreated WT-infected and WT infected-OxPAPC treated and Δ*slpA* infected eyes were due to variations in toxin production by WT and Δ*slpA B. thuringiensis*. However, the lower bacterial burden in WT infected-OxPAPC treated eyes might have resulted in a reduced cytotoxic effect on the retina which may have been reflected in the retained retinal function in OxPAPC-treated infected eyes.

Retinal detachment is a serious complication of endophthalmitis and has been reported to occur in 4--21% of cases ([@B146]). Retinal detachments, folds, and complete dissolution of retinal layers are common in severe cases of endophthalmitis ([@B5], [@B17], [@B47]). During *B. cereus* endophthalmitis, the absence of TLR2 and TLR4 in mice resulted in less infiltration of PMNs and fibrin accumulation, and preserved retinal architecture ([@B90], [@B91]). The lack of inflammation and intact retinal layers were similar to those reported in infected MyD88^−/−^ and TRIF^−/−^ eyes at 8 and 12 h postinfection ([@B97]). Here, we blocked the SLP-mediated TLR2 and TLR4 activation by OxPAPC and observed better preserved retinal architecture in the WT-infected/OxPAPC-treated and Δ*slpA-*infected groups relative to the untreated WT-infected group. We also observed elevated levels of MPO in the untreated group as compared to the treated and Δ*slpA-*infected groups. This suggests that TLR2/4 activation by SLP triggered the TLR2/4 pathways which resulted in the migration of PMNs to the eye and possibly bystander damage to the retina.

Our findings demonstrate for the first time that *Bacillus* SLP impacted endophthalmitis pathogenesis by activating both TLR2 and TLR4 pathways. In addition to identifying SLP as an unexpected TLR4 agonist, we revealed for the first time that inhibiting SLP-mediated TLR2/4 activation in experimental endophthalmitis could reduce disease severity. In *Bacillus* endophthalmitis, treatment failures are frequent despite prompt antibiotic, anti-inflammatory, and surgical intervention. Up to two-thirds of patients with *Bacillus* endophthalmitis lose significant vision, experiencing rapid inflammation and intraocular tissue damage that may also result in the need for enucleation ([@B16], [@B17]). As the number of cataract surgeries and intravitreal injections for degenerative retinal diseases continue to rise, the risk of endophthalmitis will also increase ([@B147]--[@B150]). Since TLRs and their adaptor proteins are major contributors to the initiation of potentially damaging inflammation in the eye, finding ligands that activate this pathway could be beneficial in formulating plausible strategies for therapeutic intervention to prevent vision loss in endophthalmitis caused by *Bacillus* and other bacterial pathogens.
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